ArticleFrontiers in endocrinology2025
Application of the novel tracer mitoxantrone hydrochloride in lymph node visualization during lateral neck dissection for thyroid carcinoma.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reflections on prevention and treatment of post-thyroidectomy hypoparathyroidism: current management approaches and future prospects.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In this study, a novel lymph node tracer-mitoxantrone hydrochloride injection for tracing (MHI)-was intraoperatively administered into suspected metastatic lateral cervical lymph nodes of patients with papillary thyroid carcinoma (PTC), aiming to evaluate its staining efficacy and clinical value in enhancing the completeness of lateral neck dissection (LND). Methods: A prospective controlled study was conducted at Hunan Cancer Hospital between December 2023 and May 2024, enrolling a total of 67 patients diagnosed with thyroid carcinoma. After informed consent, patients were allocated to either MHI or methylene blue group. Subjects were divided into an MHI group ( Results: The results demonstrated no statistically significant differences between the two groups in terms of operative time, total number of lymph nodes dissected, cervical drainage volume, or postoperative length of hospital stay ( Conclusion: MHI causes minimal tissue contamination and can effectively enhance the thoroughness of LND in patients with thyroid carcinoma, demonstrating high clinical application value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.